Jazz Pharmaceuticals has agreed to acquire Actio Biosciences in a transaction valued at up to $1.32 billion, adding an experimental treatment for KCNT1-related epilepsy, a rare inherited neurological disorder for which there are currently no approved therapies.
Under the terms of the agreement, Actio shareholders will receive $820 million upfront, with the potential for up to $500 million in additional payments tied to regulatory and sales milestones. The companies said the transaction is expected to close in the fourth quarter of 2026, subject to customary closing conditions.
Acquisition Centers on Experimental Therapy for KCNT1-Related Epilepsy
The primary asset involved in the deal is ABS-1230, a small-molecule precision therapy designed to target the KCNT1 ion channel. The treatment is being developed for KCNT1-related epilepsy, a severe genetic developmental and epileptic encephalopathy that affects approximately 2,500 patients in the United States.
According to Jazz, the condition often begins during infancy and can result in profound and frequent seizures that are highly resistant to available medications. Many patients experience dozens to hundreds of seizures each day. The disease can also interfere with key developmental milestones, including walking and speaking, and some patients do not survive into adulthood. In individuals who develop the condition later in life, it can present with nocturnal seizures along with cognitive and psychiatric complications.
Jazz said ABS-1230 demonstrated meaningful reductions in seizure frequency during an early proof-of-concept clinical study involving children with KCNT1-related epilepsy.
Ongoing Study Intended to Support Approval Filing
Following the initial study, Actio launched a phase 1b/2a clinical trial of ABS-1230. The study could eventually support a push for FDA approval and is intended to support a U.S. approval application.
Commenting on the treatment’s progress, Jazz Chief Executive Officer Renee Gala described ABS-1230’s clinical profile as “highly encouraging.”
The transaction builds on Jazz’s existing epilepsy business. The company entered the epilepsy field in 2021 through its acquisition of GW Pharma, which included the approved epilepsy medicine Epidiolex. Jazz reported that Epidiolex generated $292 million in revenue during the second quarter of 2026.
The company is also evaluating Epidiolex in a phase 3 study for developmental and epileptic encephalopathies and previously entered a deal with Saniona for a preclinical selective small-molecule activator of Kv7.2/Kv7.3 potassium channels aimed at patients with partial-onset seizures. Jazz’s pipeline additionally includes a phase 1-stage drug for absence epilepsy and other undisclosed epilepsy indications.
Transaction Includes Creation of New Neurology-Focused Company
Before the acquisition is completed, Actio will separate certain assets, employees, and members of its management team into a new privately held company. The spinout will focus on rare genetic neurological diseases and will be backed by Actio’s existing investors.
The new company will retain ABS-0871, a clinical-stage small-molecule TRPV4 inhibitor being developed for Charcot-Marie-Tooth type 2C, a rare inherited nerve disorder, along with other early-stage programs. Jazz will receive a minority ownership stake and certain related rights in the spinout.
The acquisition agreement gives Jazz ownership of ABS-1230. The companies said the spinout will retain certain employees and programs focused on rare neurological diseases while Jazz receives a minority stake in the new entity.
Jazz Pharmaceuticals Expands Through Actio Deal
Jazz Pharmaceuticals has agreed to acquire Actio Biosciences in a transaction valued at up to $1.32 billion.
Rare Epilepsy Creates Significant Unmet Need
KCNT1-related epilepsy is a rare neurological condition that can begin early in life and may involve frequent, difficult-to-control seizures. Patients can also experience developmental and cognitive challenges.
Because the disorder is linked to genetic changes affecting an important ion channel, researchers are exploring targeted approaches that could address the underlying biological mechanism.
Targeted Therapies Could Change Treatment
Traditional epilepsy medicines do not work equally well for every patient. Genetic information can help researchers identify specific biological pathways that may be suitable for targeted treatment.
This precision approach could eventually lead to therapies designed for smaller groups of patients based on the genetic cause of their disease.
Growing Interest in Neurology
The pharmaceutical industry continues to invest heavily in neurological disorders. Advances in genetics, molecular biology, and drug discovery are making it possible to investigate diseases that previously had limited treatment options.
Rare neurological conditions are particularly attractive for targeted drug development because a clearly defined biological pathway can provide a strong foundation for therapeutic research.
The Importance of Clinical Development
Promising laboratory and early-stage findings still need to be confirmed through well-designed clinical studies. Researchers must evaluate safety, dosing, effectiveness, and long-term outcomes before a treatment can potentially reach patients.
Later-stage trials will therefore be critical in determining whether the investigational therapy can deliver meaningful benefits.
Pediatric Patients Remain a Key Focus
KCNT1-related epilepsy can have a major impact on children and their families. Frequent seizures may interfere with development, education, sleep, and everyday activities.
Developing treatments specifically for pediatric patients can therefore have significant potential benefits, particularly when existing therapies provide inadequate seizure control.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
